Evaluation of cognitive functions and quality of life

Handbook of Clinical Neurology

Volumn 104, Issue , 2012, Pages 173-183

  Taphoorn, Martin J B ^a,b   Klein, Martin ^b  

^a MEDICAL CENTER HAAGLANDEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855531496     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52138-5.00014-1     Document Type: Chapter

References (102)

1. Aaronson N.K. Quality of life: what is it? How should it be measured?. Oncology 1988, 2:69-74.
2. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
3. Ammirati M., Vick N., Liao Y., et al. Effect of the extent of surgical resection in survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 1987, 21:201-206.
4. Archibald Y.M., Lunn D., Ruttan L.A., et al. Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 1994, 80:247-253.
5. Armstrong C.L., Goldstein B., Shera D., et al. The predictive value of longitudinal neuropsychologic assessment in the early detection of brain tumor recurrence. Cancer 2003, 97:649-656.
6. Armstrong T.S., Mendoza T., Gring I., et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol 2006, 80:27-35.
7. Armstrong T.S., Gring I., Mendoza T., et al. Clinical utility of the MDASI-BT in patients with brain metastases. J Pain Symptom Manage 2009, 37:331-340.
8. Bampoe J., Laperriere N., Pintillie M., et al. Quality of life in patients with glioblastoma multiforme participating in a randomized study of brachytherapy as a boost treatment. J Neurosurg 2000, 93:917-926.
9. Bosma I., Reijneveld J.C., Douw L., et al. Health-related quality of life of long-term high-grade glioma survivors. Neuro-oncol 2009, 11:51-58.
10. Bottomley A., Flechtner H., Efficace F. Health related quality of life outcomes in cancer clinical trials. Eur J Cancer 2005, 4:1697-1709. on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Data Center and Quality of Life Group, et al.
11. Brada M., Hoang-Xuan K., Rampling R., et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001, 12:259-266.
12. Brown P.D., Maurer M.J., Rummans T.A., et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005, 57:495-504.
13. Brown P.D., Jensen A.W., Felten S.J., et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol 2006, 24:5427-5433.
14. Brown P.D., Ballman K.V., Rummans T.A., et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol 2006, 76:283-291.
15. Brown P.D., Decker P.A., Rummans T.A., et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: comparison of patient and caregiver ratings of quality of life. Am J Clin Oncol 2008, 31:163-168.
16. Chan A.S., Cheung M.C., Law S.C., et al. Phase II study of alpha-tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer 2004, 100:398-404.
17. Clyde Z., Chataway S.J., Signorini D., et al. Significant change in tests of neurological impairment in patients with brain tumours. J Neurooncol 1998, 39:81-90.
18. Correa D., Maron L., Harder H., et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 2007, 18:1145-1151.
19. Correa D., DeAngelis L.M., Shi W., et al. Cognitive functions in low-grade gliomas: disease and treatment effects. J Neurooncol 2007, 81:175-184.
20. Cull A., Hay C., Love S.B., et al. What do cancer patients mean when they complain of concentration and memory problems?. Br J Cancer 1996, 74:1674-1679.
21. Davies E., Clarke C. Views of bereaved relatives about quality of survival after radiotherapy for malignant cerebral glioma. J Neurol Neurosurg Psychiatry 2005, 76:555-561.
22. De Haan R., Limburg M., Schuling J., et al. Clinimetric evaluation of the Barthel Index, a measure of limitations in daily activities. Ned Tijdschr Geneeskd 1993, 137:917-921.
23. Douw L., Klein M., Fagel S.S., et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 2009, 8:810-818.
24. Efficace F., Bottomley A. Health-related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer. Eur J Cancer 2002, 38:1824-1831.
25. Erharter A., Giesinger J., Kemmler G., et al. Implementation of computer-based quality-of-life monitoring in brain tumor outpatients in routine clinical practice. J Pain Symptom Manage 2010, 39:219-229.
26. Fayers P., Bottomley A. Quality of life research within the EORTC: the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002, 38:125-133.
27. Fayers P., Aaronson N., Bjordal K., et al. EORTC QLQ-C30 Scoring Manual 2001, EORTC Publications, Brussels. 3rd ed.
28. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: a practical method for grading the cognitive state for the clinician. J Psychiatr Res 1975, 12:189-198.
29. Gehring K., Sitskoorn M.M., Gundy C.M., et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol 2009, 27:3712-3722.
30. Giesinger J.M., Golser M., Erharter A., et al. Do neurooncological patients and their significant others agree on quality of life ratings?. Health Qual Life Outcomes 2009, 7:87.
31. Gill T.M., Feinstein A.R. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994, 272:619-626.
32. Giovagnoli A.R. Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumor. J Neurol Neurosurg Psychiatry 1999, 67:358-363.
33. Giovagnoli A.R., Silvani A., Colombo E., et al. Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry 2005, 76:562-568.
34. Grabenbauer G.G., Gerber K.D., Ganslandt O., et al. Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2009, 75:164-169.
35. Groenvold M., Petersen M., Aaronson N.K. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 2006, 42:55-64. for the EORTC Quality of Life Group, et al.
36. Heimans J.J., Taphoorn M.J.B. Impact of brain tumour treatment on quality of life. J Neurol 2002, 249:955-960.
37. Henriksson R., Malmström A., Bergström P., et al. High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. J Neurooncol 2006, 78:321-326.
38. Hochberg F.H., Slotnick B. Neuropsychologic impairment in astrocytoma survivors. Neurology 1980, 30:172-177.
39. Hochberg F.H., Linggood R., Wolfson L., et al. Quality and duration of survival in glioblastoma multiforme. JAMA 1979, 241:1016.
40. Imperato J.P., Paleologos N.A., Vick N.A. Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 1990, 28:818-822.
41. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. evaluation of chemotherapeutic agents 1949, 191-205. Columbia University Press, New York. C.M. Macleod (Ed.).
42. Keime-Guibert F., Chinot O., Taillandier L., et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007, 356:1527-1535.
43. Kiebert G.M., Curran D., Aaronson N.K., et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). Eur J Cancer 1998, 34:1902-1909.
44. Klein M., Taphoorn M.J.B., Heimans J.J., et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol 2001, 19:4037-4047.
45. Klein M., Heimans J.J., Aaronson N.K., et al. Mid- to long-term cognitive sequelae in low-grade gliomas: the impact of radiotherapy and other treatment-related factors. Lancet 2002, 360:1361-1368.
46. Klein M., Postma T.J., Taphoorn M.J.B., et al. The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology 2003, 61:1796-1799.
47. Kleinberg L., Wallner K., Malkin M.G. Good performance status of long-term disease-free survivors of intracranial gliomas. Int J Radiat Oncol Biol Phys 1993, 26:129-133.
48. Kocher M., Frommolt P., Borberg S.K., et al. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol 2008, 184:572-579.
49. Leibel S.A., Gutin P.H., Wara W.M., et al. Survival and quality of life after interstitial implantation of removable high-activity iodine-125 for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 1989, 17:1129-1139.
50. Levin V., Phuphanich S., Yung W.K., et al. Randomized, double-blind, placebo-controlled, clinical trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 2006, 78:295-302.
51. Lieberman A.N., Foo S.H., Ransohoff J., et al. Long term survival among patients with malignant brain tumors. Neurosurgery 1982, 10:450-453.
52. Liu R., Page M., Solheim K., et al. Quality of life in adults with brain tumors: current knowledge and future directions. Neuro-oncol 2009, 11:330-339.
53. Locke D.E., Decker P.A., Sloan J.A., et al. Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients. J Pain Symptom Manage 2007, 34:628-638.
54. Lovely M.P., Miaskowski C., Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiforme. Oncol Nurs Forum 1999, 26:921-925.
55. Mackworth N., Fobair P., Prados M.D. Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores. J Neurooncol 1992, 14:243-253.
56. Mainio A., Tuunanen S., Hakko H., et al. Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. Eur Arch Psychiatry Clin Neurosci 2006, 256:516-521.
57. Maire J.P., Coudin B., Guérin J., et al. Neuropsychological impairment in adults with brain tumors. Am J Clin Oncol 1987, 10:152-162.
58. Mauer M., Stupp R., Taphoorn M.J.B., et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer 2007, 97:302-307.
59. Mauer M.E., Taphoorn M.J.B., Bottomley A., et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. J Clin Oncol 2007, 25:5731-5737.
60. Mauer M.E., Bottomley A., Taphoorn M.J. Evaluating health-related quality of life and symptom burden in brain tumour patients: instruments for use in experimental trials and clinical practice. Curr Opin Neurol 2008, 21:745-753.
61. McCarter H., Furlong W., Whitton A.C., et al. Health status measurements at diagnosis as predictors of survival among adults with brain tumors. J Clin Oncol 2006, 24:3636-3643.
62. Meyers C.A., Hess K.R. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro-oncol 2003, 5:89-95.
63. Meyers C.A., Weitzner M.A., Valentine A.D., et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998, 16:2522-2527.
64. Meyers C.A., Hess K.R., Yung W.K., et al. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 2000, 18:646-650.
65. Meyers C.A., Smith J.A., Bezjak A., et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004, 22:157-165.
66. Murray K.J., Nelson D.F., Scott C., et al. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation and carmustine: a report of RTOG 83-02. Int J Radiat Oncol Biol Phys 1995, 31:453-459.
67. Osoba D., Aaronson N.K., Muller M., et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 1996, 5:139-150.
68. Osoba D., Aaronson N.K., Muller M., et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade malignant glioma. J Neurooncol 1997, 34:263-278.
69. Osoba D., Rodrigues G., Myles J., et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998, 16:139-144.
70. Osoba D., Brada M., Prados M.D., et al. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro-oncol 2000, 2:221-228.
71. Osoba D., Brada M., Yung W.K.A., et al. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 2000, 18:1481-1491.
72. Pickles T., Goodman G.B., Rheaume D.E., et al. Pion radiation for high grade astrocytoma: results of a randomized study. Int J Radiat Oncol Biol Phys 1997, 37:491-497.
73. Reardon D.A., Fink K.L., Mikkelsen T., et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008, 26:5610-5617.
74. Recht L., Glantz M., Chamberlain M., et al. Quantative measurement of quality outcome in malignant glioma patients using an independent living score (ILS). Assessment of a retrospective chart. J Neurooncol 2003, 61:127-136.
75. Roa W., Brasher P.M., Bauman G., et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. Int J Radiat Oncol Biol Phys 2004, 22:1583-1588.
76. Sachsenheimer W., Piotrowski W., Bimmler T. Quality of life in patients with intracranial tumors on the basis of Karnofsky's performance status. J Neurooncol 1992, 13:177-181.
77. Salo J., Niemela A., Joukamaa M., et al. Effect of brain tumour laterality on patients' perceived quality of life. J Neurol Neurosurg Psychiatry 2002, 72:373-377.
78. Schmidinger M., Linzmayer L., Becherer A., et al. Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. J Neurooncol 2003, 63:55-61.
79. Shaw E.G., Rosdhal R., D'Agostino R.B., et al. Phase II study of donezepil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 2006, 24:1415-1420.
80. Sneeuw K.C., Aaronson N.K., Osoba D., et al. The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care 1997, 35:490-506.
81. Souhami L., Seiferheld W., Brachman D., et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of RTOG 93-05 protocol. Int J Radiat Oncol Biol Phys 2004, 60:853-860.
82. Spitzer W.O., Dobson A.J., Hall J., et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 1981, 34:585-597.
83. Sprangers M.A., Aaronson N.K. The role of healthcare providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol 1992, 45:743-760.
84. Steinbach J.P., Blaicher H.P., Herrlinger U., et al. Surviving glioblastoma for more than 5 years: the patient's perspective. Neurology 2006, 66:239-242.
85. Measuring Functioning and Well-being. The Medical Outcomes Study Approach 1992, Duke University Press, Durham, NC. A.L. Stewart, J.E. Ware (Eds.).
86. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
87. Surma-aho O., Niemela M., Vilkki J., et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma survivors. Neurology 2001, 56:1285-1290.
88. Taphoorn M.J.B., Bottomley A. Health-related quality of life and symptom research in glioblastoma multiforme patients. Expert Rev Pharmacoecon Outcomes Res 2005, 5:763-774.
89. Taphoorn M.J.B., Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol 2004, 3:159-168.
90. Taphoorn M.J.B., Heimans J.J., Snoek F.J., et al. Assessment of quality of life in patients treated for low-grade glioma: a preliminary report. J Neurol Neurosurg Psychiatry 1992, 55:372-376.
91. Taphoorn M.J.B., Klein Schiphorst A.K., Snoek F.J., et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 1994, 36:48-54.
92. Taphoorn M.J.B., Stupp R., Coens C., et al. Health-related quality of life in patients with glioblastoma: a randomised clinical trial. Lancet Oncol 2005, 6:937-944.
93. Taphoorn M.J.B., van den Bent M.J., Mauer M.E., et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol 2007, 25:5723-5730.
94. Taphoorn M.J., Claassens L., Aaronson N.K. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 2010, 46:1033-1040. EORTC Quality of Life Group, and Brain Cancer, NCIC and Radiotherapy Groups, et al.
95. Taphoorn M.J., Sizoo E.M., Bottomley A. Review on quality of life issues in patients with primary brain tumors. Oncologist 2010, 15:618-626.
96. Taylor B.V., Buckner J.C., Cascino T.L. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. J Clin Oncol 1998, 16:2195-2201.
97. Trojanowski T., Peszynski J., Turowski K., et al. Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy. J Neurosurg 1989, 70:18-23.
98. Van den Bent M.J., Carpentier F.J., Brandes A.A., et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized EORTC phase III trial. J Clin Oncol 2006, 24:2715-2722.
99. Van Swieten J.C., Koudstaal P.J., Visser M.C., et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988, 19:604-607.
100. Walker M., Brown J., Brown K., et al. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. J Neurooncol 2003, 63:179-186.
101. Weitzner M.A., Meyers C.A., Gelke C.K., et al. The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995, 75:1151-1161.
102. Yung W.K., Albright R.E., Olson J., et al. A phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:588-593.